EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

Matthew D Galsky iD, Johannes Alfred Witjes, Jürgen E Gschwend, Matthew I Milowsky iD, Michael Schenker iD, Begoña P Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F Shariat iD, Se Hoon Park iD, Mads Agerbaek iD und 10 weitere

Journal of Clinical Oncology · 2025-01 · 43 (1) · 15-21

DOI: 10.1200/jco.24.00340 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-01. Verfasst von Matthew D Galsky und 21 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 128-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported . CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection. The primary end points of disease-free survival (DFS) in intent-to-treat (ITT) and tumor PD-L1 expression ≥1% populations were met. We report results at an extended median follow-up of 36.1 months in the ITT population. In addition, we report interim overall survival (OS) data for the first time and an exploratory analysis among patients with bladder primary tumors (muscle-invasive bladder cancer [MIBC]). Consistent DFS benefit with nivolumab versus placebo was observed in both the ITT (hazard ratio [HR], 0.71 [95% CI, 0.58 to 0.86]) and PD-L1 ≥1% (HR, 0.52 [95% CI, 0.37 to 0.72]) patients. The HR for OS with nivolumab versus placebo was 0.76 (95% CI, 0.61 to 0.96) in the ITT population and 0.56 (95% CI, 0.36 to 0.86) in the PD-L1 ≥1 population. Continuous benefit in nonurothelial tract recurrence-free survival and distant metastasis-free survival was also observed in both patient populations. The exploratory analysis of patients with MIBC also showed continued efficacy benefits, irrespective of PD-L1 status. No new safety signals were reported. Overall, these results further support adjuvant nivolumab as a standard of care for high-risk MIUC after radical resection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind Method

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, New York, NY.
  • Radboud University, Nijmegen, the Netherlands.
  • Technical University Munich, Munich, Germany.
  • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
  • Sf. Nectarie Oncology Center, Craiova, Romania.
  • Hospital Universitario Virgen del Rocío, Sevilla, Spain.

ORCID-Profile: Matthew D Galsky, Matthew I Milowsky, Michael Schenker, Shahrokh F Shariat, Se Hoon Park, Mads Agerbaek, Dingwei Ye, Santanu Dutta, Dean F Bajorin

Förderung

  • NCI NIH HHS

Zitieren

APA

Galsky, M. D., Witjes, J. A., Gschwend, J. E., Milowsky, M. I., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., Agerbaek, M., Jha, G., Stenner, F., Ye, D., Giudici, F., Dutta, S., Askelson, M., Nasroulah, F., …, & Bajorin, D. F. (2025). Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. Journal of Clinical Oncology, 43(1), 15-21. https://doi.org/10.1200/jco.24.00340

Vancouver

Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. Journal of Clinical Oncology. 2025;43(1):15-21. doi:10.1200/jco.24.00340

BibTeX
@article{Galsky2025,
  author = {Galsky, Matthew D and Witjes, Johannes Alfred and Gschwend, Jürgen E and Milowsky, Matthew I and Schenker, Michael and Valderrama, Begoña P and Tomita, Yoshihiko and Bamias, Aristotelis and Lebret, Thierry and Shariat, Shahrokh F and Park, Se Hoon and Agerbaek, Mads and Jha, Gautam and Stenner, Frank and Ye, Dingwei and Giudici, Fabio and Dutta, Santanu and Askelson, Margarita and Nasroulah, Federico and Zhang, Joshua and Brophy, Lynne and Bajorin, Dean F},
  title = {Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {1},
  pages = {15--21},
  doi = {10.1200/jco.24.00340}
}
Kostenlos starten →